4basebio PLC has announced a significant milestone with its client, Helix Nanotechnologies Inc., progressing into Phase I clinical trials in Australia with HN-0001, an mRNA vaccine manufactured from 4basebio's opDNA™. The Company will continue to support HelixNano with the manufacture of GMP synthetic DNA planned for later in 2024. Dr. Amy Walker, VP of Research and Business Development at 4basebio, expressed delight at the progress, stating, "It's been a pleasure to work with such an innovative company on their journey to the clinic." She also highlighted that 4basebio has several clients requiring GMP grade DNA and progressing towards clinical trials, emphasizing their commitment to supporting clients in their clinical programs.
Dr. Marianna Keaveney, Director of Clinical Product Development at HelixNano, acknowledged the milestone, stating, "It's an incredible milestone for HelixNano to secure approval for our first clinical trial, and we would not have been able to develop this drug product without the commitment of the 4basebio team." The collaboration between 4basebio and HelixNano has been instrumental in achieving this milestone, and both parties look forward to continuing their work together.
4basebio PLC is an innovation-driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company aims to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic, and pharmacological use, as well as the development of target-specific non-viral vectors for the efficient delivery of payloads in patients. Helix Nanotechnologies Inc., on the other hand, is a biotechnology company headquartered in Boston, MA, focused on building a universal interface to the immune system to tap into the innate power of the human body to fight disease, currently developing mRNA-based therapeutics in infectious disease, oncology, and other indications.
The announcement also included forward-looking statements, cautioning that any statements about the future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.